| __timestamp | CRISPR Therapeutics AG | Catalent, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5114000 | 334800000 |
| Thursday, January 1, 2015 | 13403000 | 337300000 |
| Friday, January 1, 2016 | 31056000 | 358100000 |
| Sunday, January 1, 2017 | 35845000 | 402600000 |
| Monday, January 1, 2018 | 48294000 | 462600000 |
| Tuesday, January 1, 2019 | 63488000 | 512000000 |
| Wednesday, January 1, 2020 | 88208000 | 577900000 |
| Friday, January 1, 2021 | 102802000 | 687000000 |
| Saturday, January 1, 2022 | 102464000 | 844000000 |
| Sunday, January 1, 2023 | 76162000 | 831000000 |
| Monday, January 1, 2024 | 72977000 | 935000000 |
In pursuit of knowledge
In the ever-evolving landscape of biotechnology and pharmaceuticals, operational efficiency is key. Catalent, Inc. and CRISPR Therapeutics AG, two giants in their respective fields, have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Catalent's SG&A expenses surged by approximately 148%, reflecting its aggressive expansion and operational scaling. In contrast, CRISPR Therapeutics AG, a pioneer in gene editing, saw a more modest increase of around 1,390% in the same period, albeit from a much smaller base. This disparity highlights the different growth trajectories and strategic priorities of these companies. While Catalent's expenses peaked in 2024, CRISPR's data for that year remains elusive, leaving room for speculation on its future financial strategies. As the industry continues to innovate, understanding these financial dynamics is crucial for investors and stakeholders alike.
Comparing SG&A Expenses: Eli Lilly and Company vs CRISPR Therapeutics AG Trends and Insights
Bristol-Myers Squibb Company or Catalent, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and CRISPR Therapeutics AG
Who Optimizes SG&A Costs Better? Viatris Inc. or CRISPR Therapeutics AG
Selling, General, and Administrative Costs: Catalent, Inc. vs Cytokinetics, Incorporated
Catalent, Inc. or Ionis Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Catalent, Inc. or Perrigo Company plc
Operational Costs Compared: SG&A Analysis of Opthea Limited and CRISPR Therapeutics AG
CRISPR Therapeutics AG and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
CRISPR Therapeutics AG or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
CRISPR Therapeutics AG or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and Viridian Therapeutics, Inc.